The Causal Relationship Between Passive Smoking and Inflammation on the Development of Cardiovascular Disease: A Review of the Evidence
During the past years several factors have been established as risk markers for the development of heart disease, including both active and passive smoking. Current evidence has indicated that exposure to passive smoking can lead to a 70-80% increase in the risk of coronary heart disease, nearly as much as light smoking. This disproportionate effect could possibly be explained by a number of different interactions between human physiology of the cardiovascular system and passive smoke exposure. In this review we present the different mechanisms through which passive smoking may induce an inflammatory response that may lead to the development of cardiovascular disease, on a whole and through certain of its toxic constituents. Passive smoke itself, is a volatile mixture of numerous toxins, chemicals and carcinogens, that interact with in vivo mechanisms and induce vascular damage, including endothelium inflammation, atherosclerosis development, lipid peroxidisation, alterations in cytokines and acute phase proteins (such as CRP), as well as platelet aggravation. Acting alone or in synergy, the above mentioned effects suggest a causal relationship between exposure to passive smoking and the development of cardiovascular disease.
Keywords: CRP; cardiovascular disease; inflammation; passive smoking; vascular dysfunction
Document Type: Research Article
Publication date: December 1, 2009
More about this publication?
- Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content